• 2018-07
  • 2019-04
  • 2019-05
  • 2019-06
  • 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2019-12
  • 2020-01
  • 2020-02
  • 2020-03
  • 2020-04
  • 2020-05
  • 2020-06
  • 2020-07
  • 2020-08
  • 2020-09
  • 2020-10
  • 2020-11
  • 2020-12
  • 2021-01
  • br Conclusion br Conflict of


    Conflict of interest
    Future challenges and conclusion In recent decades several anticancer drugs have been approved for the management and treatment of colorectal cancer. These drugs do not represent a revolution in the treatment of CRC. However, 5-FU has continued to be used for the treatment of tumors, and widely employed in clinical chemotherapy for the treatment of carcinomas of the colorectal region. Nevertheless, its clinical benefits are greatly limited due to drug resistance, which could result from various causes, including alteration of drug influx and efflux mechanism, enhancement of drug inactivation and mutations of the drug target.. Certainly there could be many mechanisms of 5-FU anticancer potential and drug resistance, which have yet to be demonstrated. The nano drug delivery technologies might one day enable practitioners to fabricate 5-FU and investigate the molecular mechanisms more specifically. Therefore, the urge to seek the better therapeutic strategies to increase 5-FU cytotoxicity, sensitivity and reverse resistance to drug are the key tasks in the near future.
    Conflict of interest
    Acknowledgement The author Satheesh Babu N, gratefully acknowledges the financial assistance provided by MOHE- Malaysia, in the form of Fundamental Research Grant Scheme (Ref No: FRGS/1/2014/SKK02/LINCOLN/03/1) and is also thankful to Prof. Dr. Wong Tin Wui (Non Destructive Biomed Pharmaceutical Research Centre, UiTM, Malaysia) for providing his technical and instrumentation facility. The author extends his gratitude to Kotra Pharma for providing Papain enzyme as a gift sample.
    Introduction Retroperitoneal tumor is a rare but diverse group of neoplasms that arise from the retroperitoneum, comprising about 10% of all soft tissue tumors. Managing retroperitoneal tumors is challenging because they buy Biotin-HPDP typically present at a relatively late stage, and are anatomically proximate to major vessels and vital organs. Therefore, local recurrence after surgical resection is not uncommon and significantly influences the survival of patients with retroperitoneal tumors. In this study, we aimed to analyze factors affecting outcome after surgery in our institution.
    Materials and methods
    Discussion Patients with retroperitoneal tumors often present with huge tumors (larger than 10 cm in diameter) due to their insidious location. Management of retroperitoneal tumors is generally challenging because of large tumor size and anatomical complexity. En bloc resection of organs to obtain microscopically complete clearance is the foundation of surgery for retroperitoneal tumors. Organs directly involved by the tumor should be included in the resection, but adjacent uninvolved organs should be preserved. Our study revealed that completeness of resection significantly impacts the local recurrence rate and subsequently affects the survival of patients with retroperitoneal tumors. The importance of complete extirpation of tumor has been repeatedly emphasized in the literature. It has been previously demonstrated that there is an association between histological subtype and overall survival, with better outcomes noted for patients with liposarcoma than for those with other histopathologies. Tumor grade was also reported to be a significant predictor of tumor recurrence. However, the importance of tumor grade and histology type could not be examined in our study because of small sample size in each category. Re-resection for recurrent tumors was a negative predictor for survival in this study, with a hazard ratio of 5.23. The status of presentation (primary tumor v.s. recurrent tumor) has been shown to be strongly associated with survival after surgery. However, re-resection is still the most important treatment for recurrent disease.
    Conflict of interest